Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|26/02/2013||22/05/2012||Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid||Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoidA prospective multi-centre randomised double-blind placebo-controlled pilot study - SICOPEM||Bullous pemphigoid (BP) is the most frequent blistering autoimmune disease of the skin. The disease itself is characterized by the development of bullous lesions, frequently following a prodromal phase with severe itching. Between 10 to 30 percent of patients exhibit mucosal membrane involvement in addition to the skin lesions.;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]||Trade Name: Simvastatin-ratiopharm®|
Product Name: Simvastatin-ratiopharm
Other descriptive name: SIMVASTATIN
|Philipps-Universität Marburg||NULL||Not Recruiting||Female: yes|